NervGen today announced that it has completed enrollment in the chronic cohort of its Phase 1b/2a #SpinalCordInjury clinical trial for NVG-291 and initiated screening subjects for the subacute cohort of the study. nervgen.com/nervgen-complete… #news

@NervgenP Reports 2023 Year-End Financial Results and Operational Updates: • Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 • CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 • Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord. Press release here: newsfilecorp.com/release/205…

We believe our lead drug candidate, NVG-291, has the potential to promote groundbreaking nervous system repair and functional recovery in #spinalcordinjuries, and possibly in other neurological diseases like #Stroke #Alzheimers or #MS. Watch the full video: vimeo.com/885838112?share=co…